$STRO

SUTRO BIOPHARMA, INC. (STRO): Submission of Matters to a Vote of Security Holders

SUTRO BIOPHARMA, INC. (STRO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001382101 0001382101 2026-06-05 2026-06-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2

Original reporting
Published Jun 8, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 8:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$STRO
Neutral
medium confidence
Mentioned
$STRO
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$STRONeutralLow
01

Why it matters

The disclosure confirms the board nominees were elected, Ernst & Young LLP was ratified as independent auditor for 2026, and the advisory say-on-pay proposal passed (non-binding).

02

Market read

Provides verified governance outcomes that may slightly influence sentiment but lacks new operating/financial catalysts.

03

What to watch

Traders may instead focus on whether any director contests or say-on-pay opposition could foreshadow future activism or changes in compensation strategy, though no such signal is quantified beyond vote counts here.

Relevance 6/10Novelty 5/10Timing: after-hours / filed June 8, 2026

Background

The article is an SEC Form 8-K (Item 5.07) reporting the outcomes of Sutro Biopharma’s 2026 annual stockholder meeting held June 5, 2026.

Company-level read

Ticker impact

$STRONeutralMedium confidence
Context

Sutro Biopharma filed an 8-K detailing results of its June 5, 2026 annual meeting, including director elections and auditor ratification.

Expected impact

Low likelihood of a sustained move; any reaction is likely limited to short-term sentiment around governance outcomes.

Evidence & confidence

The filing is a primary SEC disclosure of voting results, but it does not include new financial guidance, clinical data, or material transactions.

Market effects

Minimal read-across; governance vote outcomes are generally company-specific for small/mid-cap biopharma.

None.

None.

Counterpoint

Because the items are standard (director election, auditor ratification, non-binding say-on-pay), the market may ignore the details unless vote margins signal broader shareholder dissatisfaction.

Key entities

  • Sutro Biopharma, Inc.

    Nasdaq-listed biopharma company filing the 8-K with annual meeting voting results.

  • Ernst & Young LLP

    Independent registered public accounting firm ratified for the fiscal year ending Dec. 31, 2026.

Related articles

$STROMed

Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study

SUTRO BIOPHARMA, INC. (STRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study – Encouraging early clinical activity including confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK

$HAINHighAI 8/10

Hain Celestial weighs Chapter 11 filing as debt pressures build - Bloomberg

Hain Celestial (NASDAQ:HAIN) is considering a Chapter 11 bankruptcy filing due to debt pressures and weak consumer demand, according to Bloomberg. The company missed a deadline to amend its credit agreement, jeopardizing a planned asset sale. Shares fell 51%. Hain has $655M in unsecured debt and has faced operational challenges, including lawsuits over baby food products.